Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)

Overview

About this study

The purpose of this study is to assess the feasibility of enrolling, randomizing treatment strategies and retaining participants with frequent premature ventricular contractions (PVCs) and associated cardiomyopathy (CM).

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • LV dysfunction (LVEF <45%).
  • PVC burden > 10% by 2-week Holter monitor.
  • Stable optimal medical therapy for at least 3 months.

Exclusion Criteria: 

  • Current amiodarone use or within last 2 months. 
  • Current use of antiarrhythmic drugs class I or III. 
  • Contraindication to amiodarone sue or any other class III antiarrhythmic.
  • Severely symptomatic PVCs while on medical therapy (unable to complete 3-month observation period). 
  • Severe/significant CAD with planned revascularization in the near future.
  • Complete AV block and pacemaker dependent.
  • Pacemaker or ICD with >10% RV pacing. 
  • Severe valvular heart disease or planned valvular/cardiac surgery.
  • Uncontrolled / untreated endocrinopathies.
  • Uncontrolled HTN, systolic > 160mmHg.
  • Hypertrophic cardiomyopathy. 
  • Systemic infiltrative and immune disorders. 
  • Family history of dilated CM in a first degree relative. 
  • Alcohol abuse or illicit drug use. 
  • Contraindication to acute anticoagulation (possible randomization to ablation). 
  • Atrial fibrillation and flutter with rapid ventricular response with possible tachycardia-induced cardiomyopathy.
  • Possible infectious etiology of cardiomyopathy. 
  • Pregnant or lactating women.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Yongmei Cha, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions